EMEA-001202-PIP02-13-M04

Table of contents

Key facts
Decision
Related information

Key facts

Invented name	Cinqaero
Active substance	Reslizumab
Therapeutic area	Pneumology-allergology
Decision number	P/0305/2020
PIP number	EMEA-001202-PIP02-13-M04
Pharmaceutical form(s)	Concentrate for solution for infusion Solution for injection
Condition(s) / indication(s)	Treatment of asthma
Route(s) of administration	Intravenous use Subcutaneous use
Contact for public enquiries	Teva Pharmaceuticals Europe Tel. +44 (0)20 7540 7117 E-mail: medinfo@tevauk.com
Decision type	PM: decision on the application for modification of an agreed PIP

Decision

List item

P/0305/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for reslizumab (Cinqaero) (EMEA-001202-PIP02-13-M04) (PDF/293.34 KB)

Adopted

First published: 28/06/2021
EMA/413459/2020

Related content

Cinqaero: EPAR

Related information

List item

Public summary of the evaluation of a proposed paediatric investigation plan: Reslizumab for treatment of asthma (PDF/92.3 KB)

First published: 10/03/2015
Last updated: 10/03/2015
EMA/112434/2015

How useful was this page?

Add your rating

★ ★ ★ ★ ★